One-Year Outcomes of Transcatheter Aortic Valve Replacement in Patients With End-Stage Renal Disease

Using data from the CoreValve US Expanding Use Study, outcomes for patients with end stage renal disease (ESRD) undergoing TAVR were evaluated using an endpoint of all-cause mortality or major stoke at 1 year.  Mortality at 1 year was 30%, and the stroke incidence was 2.1%.  New permanent pacemaker need was 27%.  The 1-year mortality appears increased compared to patients without ESRD.